WO2002079377A3 - Antibodies that immunospecifically bind to trail receptors - Google Patents

Antibodies that immunospecifically bind to trail receptors Download PDF

Info

Publication number
WO2002079377A3
WO2002079377A3 PCT/US2001/042996 US0142996W WO02079377A3 WO 2002079377 A3 WO2002079377 A3 WO 2002079377A3 US 0142996 W US0142996 W US 0142996W WO 02079377 A3 WO02079377 A3 WO 02079377A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
immunospecifically bind
relates
trail receptors
trail
Prior art date
Application number
PCT/US2001/042996
Other languages
French (fr)
Other versions
WO2002079377A2 (en
Inventor
Theodora Salcedo
Victor Roschke
Steven M Ruben
Craig A Rosen
Original Assignee
Human Genome Sciences Inc
Theodora Salcedo
Victor Roschke
Steven M Ruben
Craig A Rosen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Theodora Salcedo, Victor Roschke, Steven M Ruben, Craig A Rosen filed Critical Human Genome Sciences Inc
Priority to AU2001297702A priority Critical patent/AU2001297702A1/en
Priority to CA002426710A priority patent/CA2426710A1/en
Priority to EP01273517A priority patent/EP1339426A4/en
Publication of WO2002079377A2 publication Critical patent/WO2002079377A2/en
Publication of WO2002079377A3 publication Critical patent/WO2002079377A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptors. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TRAIL receptor antibodies, vectors, and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor.
PCT/US2001/042996 2000-11-08 2001-11-07 Antibodies that immunospecifically bind to trail receptors WO2002079377A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001297702A AU2001297702A1 (en) 2000-11-08 2001-11-07 Antibodies that immunospecifically bind to trail receptors
CA002426710A CA2426710A1 (en) 2000-11-08 2001-11-07 Antibodies that immunospecifically bind to trail receptors
EP01273517A EP1339426A4 (en) 2000-11-08 2001-11-07 Antibodies that immunospecifically bind to trail receptors

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US24661200P 2000-11-08 2000-11-08
US60/246,612 2000-11-08
US24884700P 2000-11-16 2000-11-16
US60/248,847 2000-11-16
US25290400P 2000-11-27 2000-11-27
US60/252,904 2000-11-27
US29501801P 2001-06-04 2001-06-04
US60/295,018 2001-06-04
US32735901P 2001-10-09 2001-10-09
US60/327,359 2001-10-09

Publications (2)

Publication Number Publication Date
WO2002079377A2 WO2002079377A2 (en) 2002-10-10
WO2002079377A3 true WO2002079377A3 (en) 2003-03-13

Family

ID=27540243

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/042996 WO2002079377A2 (en) 2000-11-08 2001-11-07 Antibodies that immunospecifically bind to trail receptors

Country Status (4)

Country Link
EP (1) EP1339426A4 (en)
AU (1) AU2001297702A1 (en)
CA (1) CA2426710A1 (en)
WO (1) WO2002079377A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
CN100475848C (en) 2001-05-18 2009-04-08 麒麟麦酒株式会社 Anti-TRAIL-R antibodies
EP1531162A1 (en) * 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
JP5562521B2 (en) 2005-02-02 2014-07-30 ザ ユーエービー リサーチ ファンデーション Agents and methods relating to reducing resistance to apoptosis-inducing death receptor agonists
US7915245B2 (en) 2007-02-01 2011-03-29 The Board Of Regents Of The University Of Texas System Methods and compositions of trail-death receptor agonists/activators
EA201890895A1 (en) 2013-03-15 2019-02-28 Зинджения, Инк. MULTIVALENT AND MONOVALENT MULTIS-SPECIFIC COMPLEXES AND THEIR APPLICATION

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763223A (en) * 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
WO1999012963A2 (en) * 1997-09-12 1999-03-18 Biogen, Inc. Cysteine rich receptors: trail
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1012274E (en) * 1997-01-28 2007-08-14 Craig A Rosen Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l)
IL137176A0 (en) * 1998-01-26 2001-07-24 Genentech Inc Antibodies to 4dr and uses thereof
ES2331901T3 (en) * 1998-06-12 2010-01-19 Genentech, Inc. MONOCLONAL ANTIBODIES, ANTIBODIES THAT REACT IN A CROSSED FORM AND PROCEDURE FOR THE PRODUCTION OF THE SAME.
EP2281843B1 (en) * 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763223A (en) * 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
WO1999012963A2 (en) * 1997-09-12 1999-03-18 Biogen, Inc. Cysteine rich receptors: trail

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1339426A4 *

Also Published As

Publication number Publication date
WO2002079377A2 (en) 2002-10-10
CA2426710A1 (en) 2002-10-10
EP1339426A2 (en) 2003-09-03
AU2001297702A1 (en) 2002-10-15
EP1339426A4 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
WO2003054216A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2002097033A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2002094192A3 (en) Antibodies against tumor necrosis factor delta (april)
MXPA02012434A (en) Antibodies that immunospecifically bind to blys.
WO2003055979A3 (en) ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
WO2001001748A3 (en) Peptide compounds that bind her2
WO2001055448A8 (en) Nucleic acids, proteins, and antibodies
WO2004100898A3 (en) Therapeutic use of anti-cs1 antibodies
WO2004013287A3 (en) Antibodies against c3a receptor
WO2002016411A3 (en) Binding polypeptides and methods based thereon
BR0306973A (en) Anti-igf-ir Antibodies and their applications
WO2005016236A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2003089575A3 (en) Antibodies that specifically bind to tl5
WO2003085093A3 (en) Antibodies that specifically bind to gmad
WO2002036625A3 (en) Prokineticin polypeptides, related compositions and methods
WO2004003144A3 (en) Antibodies that specifically bind to reg iv
WO2003102136A3 (en) Antibodies that specifically bind to neurokinin b
WO2002079377A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2003042367A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2004016753A3 (en) Antibodies that immunospecifically bind to trail receptors
ATE518884T1 (en) ANTIBODIES SPECIFICALLY BINDING TO CHEMOKIN BETA-4
WO2003086301A3 (en) Antibodies that specifically bind to tr2
WO2005018536A3 (en) Agonist antibodies that specifically bind the glucagon like peptide-1 receptor
WO2002100343A3 (en) N-terminally truncated galectin-3 and antibodies for treating cancer
CY1114921T1 (en) ANTIOPODIES BINDING ON TRAIL RECEPTORS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2426710

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001273517

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001273517

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001273517

Country of ref document: EP